Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 19/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 16/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 16/20 | 0.43 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.37 |
| ▸ | TACR1 | P25103 | 2/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.37 |
| ▸ | HRH1 | P35367 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL8512097 | 0.94 | CHRM3 (0.39) | CHRM3CHRM2CHRM1GPR132CHRM4 | |
| SCHEMBL9289992 | 0.93 | CHRM3 (0.43) | CHRM3CHRM2CHRM1GPR132CHRM4 | |
| SCHEMBL13282534 | 0.89 | CHRM3 (0.43) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL13240930 | 0.89 | CHRM3 (0.43) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL8509770 | 0.88 | CHRM3 (0.42) | CHRM3CHRM2CHRM1GPR132 | |
| Bromide SCHEMBL2992962 | 0.88 | CHRM3 (0.44) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Bromide SCHEMBL2524921 | 0.88 | CHRM3 (0.44) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trifluoroacetic Acid SCHEMBL17667714 | 0.88 | CHRM3 (0.39) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL9288972 | 0.87 | CHRM3 (0.43) | CHRM3CHRM2CHRM1GPR132 | |
| SCHEMBL13240998 | 0.87 | CHRM3 (0.42) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772314-B2 | Glycine derivatives and medicinal compositions thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-07-08 | — | — | US | disclosed |
| US-20120134934-A1 | GLYCINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-05-31 | — | — | US | disclosed |
| WO-2012069275-A1 | GLYCINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134934-A1 | GLYCINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | CHRM3, GLRB, CHRNG | CHRM3 1/4885CHRM2 4/4885CHRM1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.